Loading
HKSEHealthcareBiotechnology
Latest quote
HK$3.985
HK$0.00 · 0.00%
Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The company's therapeutic candidates encompass a range of modalities, including cutting-edge antibody-drug conjugates (ADCs), oncolytic virus treatments, and diverse immunotherapies. Among its immuno-oncology offerings are HX008 (an anti-PD-1 mAb) and LP002 (an anti-PD-L1 mAb). The ADC portfolio features MRG003 (targeting EGFR), MRG002 (targeting HER2), MRG001 (targeting CD20), MRG004A (targeting TF), and CMG901 (targeting CLDN18.2). Additionally, Lepu Biopharma is advancing the oncolytic virus CG0070, along with various combination therapies such as HX008+OH2, LP002+OH2, and HX008+LP002. Founded in 2018, the company is headquartered in Shanghai, China.
Latest quote
HK$3.985
HK$0.00 · 0.00%
Regular session · HKT · Market data may be delayed.
Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The company's therapeutic candidates encompass a range of modalities, including cutting-edge antibody-drug conjugates (ADCs), oncolytic virus treatments, and diverse immunotherapies. Among its immuno-oncology offerings are HX008 (an anti-PD-1 mAb) and LP002 (an anti-PD-L1 mAb). The ADC portfolio features MRG003 (targeting EGFR), MRG002 (targeting HER2), MRG001 (targeting CD20), MRG004A (targeting TF), and CMG901 (targeting CLDN18.2). Additionally, Lepu Biopharma is advancing the oncolytic virus CG0070, along with various combination therapies such as HX008+OH2, LP002+OH2, and HX008+LP002. Founded in 2018, the company is headquartered in Shanghai, China.
Day range
Current HK$3.985
52-week range
Current HK$3.985
Regular session · HKT · Market data may be delayed.
Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The company's therapeutic candidates encompass a range of modalities, including cutting-edge antibody-drug conjugates (ADCs), oncolytic virus treatments, and diverse immunotherapies. Among its immuno-oncology offerings are HX008 (an anti-PD-1 mAb) and LP002 (an anti-PD-L1 mAb). The ADC portfolio features MRG003 (targeting EGFR), MRG002 (targeting HER2), MRG001 (targeting CD20), MRG004A (targeting TF), and CMG901 (targeting CLDN18.2). Additionally, Lepu Biopharma is advancing the oncolytic virus CG0070, along with various combination therapies such as HX008+OH2, LP002+OH2, and HX008+LP002. Founded in 2018, the company is headquartered in Shanghai, China.
Day range
Current HK$3.985
52-week range
Current HK$3.985
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 910.67M CNY | 367.79M CNY | 225.35M CNY | 15.57M CNY | — |
| Cost of goods sold | 178.57M CNY | 74.82M CNY | 28.28M CNY | 2.01M CNY | 114.79M CNY |
| Gross profit | 732.1M CNY | 292.97M CNY | 197.08M CNY | 13.57M CNY | −114.79M CNY |
| Research and development | 335.57M CNY | 437.7M CNY | 458.07M CNY | 524.29M CNY | 791.21M CNY |
| Selling, general, and administrative | 354.46M CNY | 237.89M CNY | 129.95M CNY | 140.58M CNY | 156.24M CNY |
| Operating expenses | 644.67M CNY | 683.74M CNY | 192.28M CNY | 718.05M CNY | 1.01B CNY |
| Interest income | 12.01M CNY | 4.67M CNY | 6.71M CNY | 8.17M CNY | 4.14M CNY |
| Interest expense | 28.55M CNY | 21.65M CNY | 14.68M CNY | 7.47M CNY | 2.7M CNY |
| Depreciation and amortization | 91.3M CNY | 83.91M CNY | 102.57M CNY | 95.45M CNY | 77.18M CNY |
| Operating income | 87.43M CNY | −390.77M CNY | 4.8M CNY | −704.48M CNY | −1.01B CNY |
| Net income | 254.6M CNY | −411.38M CNY | −22.1M CNY | −689.05M CNY | −1.01B CNY |
Company facts updated Sep 15, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core MSCI Emerging Markets ETFIEMG6.45M0.00%163.33B USD0.09%$80.10-0.37%
State Street SPDR Portfolio Emerging Markets ETFSPEM1.02M0.01%17.7B USD0.07%$51.55-0.73%
WisdomTree China ex-State-Owned Enterprises FundCXSE333.85K0.07%466.19M USD0.32%$35.9763-0.91%
iShares Core MSCI Total International Stock ETFIXUS244.88K0.00%60.28B USD0.07%$95.56-0.41%
Avantis Emerging Markets Equity ETFAVEM242.71K—28.2B USD0.33%$92.54-0.64%
Global X - Aging Population ETFAGNG185.95K0.20%90.29M USD0.50%$36.8908-0.53%
iShares MSCI China Small-Cap ETFECNS182.9K0.29%63.56M USD0.59%$27.66-1.22%
iShares MSCI Emerging Markets Small-Cap ETFEEMS121.93K0.03%389.01M USD0.72%$74.355-0.92%iShares Core MSCI Emerging Markets ETFIEMGState Street SPDR Portfolio Emerging Markets ETFSPEMWisdomTree China ex-State-Owned Enterprises FundCXSEiShares Core MSCI Total International Stock ETFIXUSAvantis Emerging Markets Equity ETFAVEMGlobal X - Aging Population ETFAGNGiShares MSCI China Small-Cap ETFECNSiShares MSCI Emerging Markets Small-Cap ETFEEMSAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
